{"id":"W4403267451","doi":"10.1016/j.isci.2024.111108","title":"Preclinical validation of human recombinant glutamate-oxaloacetate transaminase for the treatment of acute ischemic stroke","year":2024,"lang":"en","type":"article","venue":"iScience","topic":"Neurological Disease Mechanisms and Treatments","field":"Neuroscience","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institut National de la Recherche Scientifique","funders":"Agencia Estatal de Investigación; Instituto de Salud Carlos III; European Research Council; Fonds de Recherche du Québec - Santé; Institut national de la recherche scientifique; Xunta de Galicia; Consellería de Economía, Emprego e Industria, Xunta de Galicia; Ministerio de Ciencia e Innovación; Fundación Mutua Madrileña; European Regional Development Fund; European Commission; Federación Española de Enfermedades Raras; EuroNanoMed III","keywords":"Transaminase; Glutamate receptor; Recombinant DNA; Stroke (engine); Medicine; Citrate synthase; Aspartate transaminase; Biochemistry; Pharmacology; Chemistry; Internal medicine; Neuroscience; Biology; Enzyme; Alkaline phosphatase","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001493192,0.0001248579,0.0001773044,0.00004440657,0.0001434351,0.00003936806,0.0002656544,0.00003424937,0.00003999854],"category_scores_gemma":[0.00004614033,0.00006747234,0.0001976903,0.0002090451,0.0002519936,0.0001241819,0.0000189176,0.00003986709,0.000008726362],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002009686,"about_ca_system_score_gemma":0.00003760746,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000008653004,"about_ca_topic_score_gemma":9.688891e-7,"domain_scores_codex":[0.9987909,0.00005461388,0.0002867452,0.0004288302,0.0002339286,0.0002049481],"domain_scores_gemma":[0.9990497,0.0005307764,0.00008301064,0.0002539483,0.00002267357,0.00005985467],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00007307401,0.000541942,0.00004967591,0.0000293193,0.00002060441,0.00002356389,0.0001756847,0.00002426974,0.9804406,0.002966493,0.00002320019,0.01563156],"study_design_scores_gemma":[0.000514702,0.002323997,0.0004451801,0.00001972773,0.0001749533,0.000005572314,0.00001006558,0.002590338,0.9911994,0.00185755,0.0007929604,0.00006557781],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9966429,0.0002396609,0.001292933,0.0002862386,0.000381547,0.0006256631,0.0002875605,0.00003930326,0.0002041705],"genre_scores_gemma":[0.9985215,0.0003567543,0.0001342543,0.00003572141,0.00001223182,0.0001133874,0.000003517566,0.00000847811,0.0008141375],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01556598,"threshold_uncertainty_score":0.2751442,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08261990111822587,"score_gpt":0.3563263450952718,"score_spread":0.2737064439770459,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}